Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Orlistat: they're closely matched on evidence (4.5 vs 6/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Canagliflozin and Orlistat are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Orlistat have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (canagliflozin)
Prescription Xenical: 120 mg three times daily (360 mg/day), taken with or up to 1 hour after each main fat-containing meal. Over-the-counter Alli: 60 mg three times daily (180 mg/day). Skip the dose if a meal is missed or contains no fat. Used alongside a reduced-calorie diet in which fat supplies roughly 30% of energy — a higher-fat meal makes the gastrointestinal side effects markedly worse, not the weight loss better.
with-meals
Xenical 120 mg capsule three times daily with meals (prescription)
Unknown in humans
Months to years
Weeks to months
Throughout use
4–12 weeks to onset; maximal by 6–12 months
Year 2 of continuous use
Years
3–12 months
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Diabetes Care (2004) · Rct · n=3305
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Lancet (1998) · Rct · n=688
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
JAMA (1999) · Rct · n=892
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Both Canagliflozin and Orlistat are closely matched — the best choice depends on your specific health goals.
For manage weight, Orlistat has a higher relevance score (72 vs 45).
No known interactions between Canagliflozin and Orlistat have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.